diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index f8c3dfe2e..3030e8f83 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -38,13 +38,13 @@ SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semagluti ### Additional Evidence (extend) -*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16* +*Source: 2025-05-01-nejm-semaglutide-mash-phase3-liver | Added: 2026-03-16* Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo. Meta-analysis confirms GLP-1 RAs significantly increase histologic resolution of MASH, decrease liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation. Some hepatoprotective benefits appear at least partly independent of weight loss, suggesting direct liver effects beyond metabolic improvement. This adds hepatic protection as a third major organ system (alongside cardiovascular and renal) where GLP-1s demonstrate protective effects. ### Additional Evidence (confirm) -*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* +*Source: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes | Added: 2026-03-16* FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors. diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index b5699bd0b..95c019c28 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -30,7 +30,7 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, ### Additional Evidence (confirm) -*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* +*Source: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes | Added: 2026-03-16* FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR decline slowed by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early at prespecified interim analysis due to efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM. diff --git a/entities/internet-finance/metadao.md b/entities/internet-finance/metadao.md index 4d5b44b05..34955c942 100644 --- a/entities/internet-finance/metadao.md +++ b/entities/internet-finance/metadao.md @@ -58,8 +58,8 @@ The futarchy governance protocol on Solana. Implements decision markets through - **2024-03-02** — [[metadao-increase-meta-liquidity-dutch-auction]] passed: completed Dutch auction and liquidity provision, moving all protocol-owned liquidity to Meteora 1% fee pool - **2025-01-27** — [[metadao-otc-trade-theia-2]] proposed: Theia offers $500K for 370.370 META at 14% premium with 12-month vesting - **2025-01-30** — [[metadao-otc-trade-theia-2]] passed: Theia acquires 370.370 META tokens for $500,000 USDC -- **2023-11-18** — [[metadao-develop-lst-vote-market]] proposed: first product development proposal requesting 3,000 META to build Votium-style validator bribe platform for MNDE/mSOL holders -- **2023-11-29** — [[metadao-develop-lst-vote-market]] passed: approved LST Vote Market development with projected $10.5M enterprise value addition +- **2023-11-18** — metadao-develop-lst-vote-market proposed: first product development proposal requesting 3,000 META to build Votium-style validator bribe platform for MNDE/mSOL holders +- **2023-11-29** — metadao-develop-lst-vote-market passed: approved LST Vote Market development with projected $10.5M enterprise value addition - **2023-12-03** — Proposed Autocrat v0.1 migration with configurable proposal slots and 3-day default duration - **2023-12-13** — Completed Autocrat v0.1 migration, moving 990,000 META, 10,025 USDC, and 5.5 SOL to new program despite unverifiable build - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG)